LNTH - Lantheus a undervalued biotech company!

Lantheus is a undervalued biotech play. With their current pipeline I believe many are missing out on a easy biotech cash cow play. Lantheus is a medical imaging company. FDA recently approved a new formulation for PYLARIFY. PYLARIFY is used for prostate cancer. The new formulation improvements are expected to increase batch sizes, to reach more patients and serve broader geographic markets.  PYLARIFY is recognized as the leading PSMA PET imaging agent, with extensive use across the United States. PYLARIFY (piflufolastat F 18) is the #1 ordered PSMA PET imaging agent in the U.S. for detecting prostate cancer, utilized in over 760,000+ scans. NEURACEQ \\\*\\\*\\\*is used to help diagnose Alzheimer's disease and other cognitive (mental) problems\\\*\\\*\\\*. Recent quarter the sales of Neuraceq was $31 million. The quarter before that sales came in around $20 million. Lantheus sales team is very good a promoting their medical imaging agents. Pylarify is a blockbuster imaging agent. I expect neuraceq to do the same. Dementia is a rapidly growing crisis in the U.S.